Abstract
Despite recent advances in nanomedicine, developing multifunctional nanocarriers capable of targeted subcellular delivery and efficient gene therapy remains a significant challenge. This study reports the design, synthesis, and evaluation of a novel multifunctional polypeptide-based nanoconjugate that addresses this gap using sequential delivery, combining mitochondrial targeting and nonviral gene therapy. We engineered a poly-l-ornithine-based, polyethylene glycol-modified carrier and introduced a novel custom-designed trivalent compound (TRV3) into the structure. TRV3, conjugated to the polypeptide carrier via a redox-sensitive disulfide linker, incorporates the well-described triphenylphosphonium moiety (TPP) for mitochondrial targeting and a Cy5 fluorophore as a model drug. The resulting nanoconjugate (C-TRV3-A) demonstrated efficient endosomal escape and mitochondrial localization. Leveraging the endosomolytic properties of C-TRV3-A, we explored its potential as a nonviral vector for gene therapy. After optimizing formulation stability using a VLC-3 anionic polypeptide coating, we developed plasmid DNA polyplexes that exhibited enhanced stability and transfection efficiency in basic and advanced triple-negative breast cancer cell culture models. This multifunctional polypeptide-based nanoconjugate represents a significant advance in the field, offering a chemically versatile platform for simultaneous subcellular targeting and gene delivery that may be used in targeted cancer treatments, among other pathologies.